Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay

Cancer Research

Volumn 48, Issue 3, 1988, Pages 584-588

  Alley, Michael C ^a   Scudiero, Dominic A ^a   Monks, Anne ^a   Hursey, Miriam ^a   Czerwinski, Maciej J ^a   Fine, Donald L ^a   Abbott, Betty J ^b   Mayo, Joseph G ^b   Shoemaker, Robert ^b   Boyd, Michael R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; TETRAZOLIUM;

CELL CULTURE; COLORIMETRY; CYTOLOGY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; MALE; METHODOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; COLORIMETRY; DRUG EVALUATION, PRECLINICAL; FORMAZANS; HUMAN; OXIDATION-REDUCTION; SOLVENTS; SPECTRUM ANALYSIS; SUPPORT, U.S. GOV'T, P.H.S.; TETRAZOLIUM SALTS; TUMOR CELLS, CULTURED;

EID: 84965822602     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. I, Chapter 1, Cancer therapy: Where do we go from here? pp. 68–76. Philadelphia: Lippincott, 1986.
2. National Cancer Institute planning to switch drug development emphasis from compound to human cancer-oriented strategy. Cancer Lett., 10: 1–3, 1984.
3. Division of Cancer Treatment Board approves new screening program, natural products concepts. Cancer Lett., 11:4-8, 1985.
4. Boyd, M. R., Shoemaker, R. H., McLemore, T. L., Johnston, M. R., Alley, M. C., Scudiero, D. A., Monks, A., Fine, D. L., Mayo, J. G., and Chabner, B. A. New Drug Development. in: J. A. Roth, J. C. Ruckdescher, and T. H. Weisenburger (eds.), Thoracic Oncology, Chap. 51. New York: W. B. Saunders Co., in press.
5. Workshop on “Disease-oriented antitumor drug discovery and development, NIH, Bethesda, MD, Jan 9-10,1985. Sponsored by Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute.
6. Ad Hoc review committee proceedings for National Cancer Institute In Vitro/In Vivo Disease Oriented Screening Project. NIH, Bethesda, MD, Sept. 23–24, 1985. Sponsored by Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute.
7. Ad Hoc review committee proceedings for National Cancer Institute In Vitro/In Vivo Disease Oriented Screening Project. NIH, Bethesda, MD, Dec. 8–9, 1986. Sponsored by Developmental Therapeutics Program, Division of Cancer Treatment National Cancer Institute.
8. Frei, E. The national chemotherapy program. Science (Wash. DC), 217: 600-606,1982.
9. Venditti, J. M. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary. Cancer Treat. Rep., 67:767-772,1983.
10. Salmon, S. E., Hamberger, A. W., Soehnlen, B., Durie, B. G., Alberts, D. S., and Mood, T. E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N. Engl. J. Med., 298: 1321–1327, 1978.
11. Shoemaker, R. H., Wolpert-DeFilippes, M. K., Kern, D. H., Lieber, M. M., Makuch, R. W., Melnick, N. R., Miller, W. T., Salmon, S. E., Simon, R. M., Venditti, J. M., and Von Hoff, D. Application of a human tumor colony-forming assay to new drug screening. Cancer Res., 45: 2145–2153, 1985.
12. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Meth., 65: 55–63, 1983.
13. Finlay, G. J., Baguley, B. L., and Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem., 139: 272–277, 1984.
14. Shipley, G. D., and Ham, R. G. Improved medium and culture conditions for clonal growth with minimal serum proteins and for enhanced serum-free survival of Swiss 3T3 cells. In Vitro (Rockville), 17:656-669,1981.
15. Epstein, S. L., and Lunney, J. K. A cell surface ELISA in the mouse using only poly-L-lysine as cell fixative. J. Immunol. Meth., 76:63-72,1985.
16. In Vivo Cancer Models. NIH Publication No. 84–2635. Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 1984.